ALNOV:EPA
Novacyt SA
0,44 €
0,00%
(0,00) 1 p
19. nov, 17:35:19 GMT +1 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse ALNOV põhistatistika genereerimine…
Ava
0,44 €
Kõrge
0,45 €
Madal
0,44 €
Turu kapit.
31,86 mln
Keskm. maht
136,90 tuh
Maht
94,87 tuh
52 näd kõrgeim
1,04 €
52 näd madalaim
0,29 €
Aktsiatulu
−0,38 €
Käibivad aktsiad
72,59 mln
Töötajate arv
228
Ava
0,44 €
Kõrge
0,45 €
Madal
0,44 €
Turu kapit.
31,86 mln
Keskm. maht
136,90 tuh
Maht
94,87 tuh
52 näd kõrgeim
1,04 €
52 näd madalaim
0,29 €
Aktsiatulu
−0,38 €
Käibivad aktsiad
72,59 mln
Töötajate arv
228
Uudised
Veebiallikatest ja uudistepartneritelt
Benzinga
·
49 minuti eest
Anthropic Jumps 27% in Record Debut, S&P 500 Eyes Sixth Straight Loss: Stock Market Today
The Motley Fool
·
8 tunni eest
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
24/7 Wall St.
·
5 tunni eest
Want Reliable Retirement Income? Invest in These 3 Dow Jones Passive Income Dividend Stocks
Traders Union
·
1 tunni eest
Charlie Bilello: S&P 500 langes oktoobri tipust 8%, suurim langus alates märtsist
Profiil
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Teave üksuse Novacyt SA kohta
TegevjuhtDavid Allmond
Töötajad228
Asutatud3. juuli 2006
Peakontorid-
SektorHealth Care
Valdkond-
Veebisaitnovacyt.com